Placebo + Gevokizumab
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Behcet's Disease Uveitis
Conditions
Behcet's Disease Uveitis
Trial Timeline
Nov 1, 2014 → Nov 1, 2015
NCT ID
NCT02258867About Placebo + Gevokizumab
Placebo + Gevokizumab is a phase 3 stage product being developed by XOMA for Behcet's Disease Uveitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02258867. Target conditions include Behcet's Disease Uveitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02258867 | Phase 3 | Terminated |
| NCT01882491 | Phase 2 | Completed |
| NCT01683396 | Phase 2 | Completed |
Competing Products
2 competing products in Behcet's Disease Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rituximab + Cytotoxic Combination | Roche | Phase 2 | 52 |
| Abatacept | Bristol Myers Squibb | Phase 1 | 32 |